Marshall Urist, EVP, Research & Investments at Royalty Pharma plc (RPRX), sold 9,098 shares at $55.18 ($502K) on 2026-06-24, disclosed to the SEC on 2026-06-25.
Scheduled sale ($502k) by EVP, Research & Investments under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| RPRX | SELL | 2026-07-02 | $508K | — | Filing → |
| RPRX | SELL | 2026-05-21 | $722K | — | Filing → |
| RPRX | SELL | 2026-05-15 | $726K | — | Filing → |